- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Orchid Pharma Limited — Board Meeting, 11-02-2026: Outcome of Board Meeting
11-02-2026 | 05:42 pm
11-02-2026 | 05:42 pm
Orchid Pharma's Board approved Q3 FY26 consolidated results. Net sales stood at ₹207.27 Cr. The company posted a net loss of ₹12.61 Cr, impacted by an exceptional ₹7.11 Cr employee benefits liability. EPS was (₹2.49).
No comments yet. Be the first to comment!